ArticleBritish journal of cancer2020

Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer.

Zeting Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.